Longeveron Inc.
About Longeveron Inc.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $1.2M
- Net income
- -$22.7M
- Total assets
- $10.3M
- Market cap
- $23.1M
- Gross margin
- 78.8%
- Operating margin
- -690.7%
- Net margin
- -667.8%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $2.4M
- Cost of revenue
- $508.0K
- Gross profit
- $1.9M
- Operating expenses
- $18.4M
- Operating income
- -$16.5M
- Income tax
- $0
- Net income
- -$16.0M
- EPS (basic)
- $-2.62
- EPS (diluted)
- $-2.62
Balance sheet
- Total assets
- $25.6M
- Current assets
- $19.6M
- Total liabilities
- $3.7M
- Current liabilities
- $2.6M
- Shareholders’ equity
- $21.9M
Cash flow
- Operating cash flow
- -$13.9M
- Investing cash flow
- -$640.0K
- Financing cash flow
- $28.8M
- Net cash flow
- $14.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $23.1M
- EPS (diluted)
- $-2.62
- Shares outstanding
- 30.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 12, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $22.7M in FY2025.
- Revenue grew 83% from FY2021 to FY2024.
- Gross margin of 78.8%, net margin -667.8%.
- Trading 57% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Longeveron Inc..
Write a review
News about Longeveron Inc.
News & sentiment via Polygon.io
